GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Cyclically Adjusted PS Ratio

Peptron (XKRX:087010) Cyclically Adjusted PS Ratio : 942.62 (As of Jun. 04, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Cyclically Adjusted PS Ratio?

As of today (2025-06-04), Peptron's current share price is ₩230000.00. Peptron's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩244.00. Peptron's Cyclically Adjusted PS Ratio for today is 942.62.

The historical rank and industry rank for Peptron's Cyclically Adjusted PS Ratio or its related term are showing as below:

XKRX:087010' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 96.88   Med: 351.42   Max: 952.87
Current: 942.64

During the past years, Peptron's highest Cyclically Adjusted PS Ratio was 952.87. The lowest was 96.88. And the median was 351.42.

XKRX:087010's Cyclically Adjusted PS Ratio is ranked worse than
98.99% of 497 companies
in the Biotechnology industry
Industry Median: 5.61 vs XKRX:087010: 942.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Peptron's adjusted revenue per share data for the three months ended in Mar. 2025 was ₩69.751. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₩244.00 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Peptron Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Peptron's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Cyclically Adjusted PS Ratio Chart

Peptron Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 414.79

Peptron Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 107.48 195.00 211.26 414.79 377.05

Competitive Comparison of Peptron's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Peptron's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Peptron's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Peptron's Cyclically Adjusted PS Ratio falls into.


;
;

Peptron Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Peptron's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=230000.00/244.00
=942.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Peptron's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Peptron's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=69.751/122.5900*122.5900
=69.751

Current CPI (Mar. 2025) = 122.5900.

Peptron Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 48.232 100.051 59.098
201509 76.010 100.111 93.078
201512 52.953 100.220 64.772
201603 56.537 100.561 68.922
201606 67.462 100.791 82.053
201609 70.630 101.461 85.338
201612 72.633 101.561 87.672
201703 42.481 102.851 50.634
201706 20.582 102.611 24.589
201709 42.834 103.491 50.739
201712 94.975 102.991 113.049
201803 39.409 104.101 46.408
201806 25.008 104.130 29.441
201809 68.511 105.651 79.496
201812 59.631 104.351 70.054
201903 37.845 104.491 44.400
201906 34.938 104.881 40.837
201909 22.886 105.200 26.669
201912 21.512 105.121 25.087
202003 30.452 105.354 35.434
202006 54.901 105.112 64.030
202009 55.672 106.198 64.265
202012 62.880 105.765 72.883
202103 39.251 107.357 44.820
202106 203.742 107.579 232.172
202109 40.174 108.759 45.283
202112 38.212 109.676 42.711
202203 134.417 111.848 147.327
202206 48.949 114.072 52.604
202209 59.687 114.715 63.784
202212 38.398 115.179 40.869
202303 56.260 116.507 59.197
202306 33.780 117.182 35.339
202309 33.180 118.964 34.191
202312 38.957 118.837 40.187
202403 23.208 120.123 23.685
202406 26.341 120.007 26.908
202409 28.623 120.861 29.032
202412 72.289 121.135 73.157
202503 69.751 122.590 69.751

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Peptron  (XKRX:087010) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Peptron Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Peptron's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Peptron Business Description

Industry
Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron Headlines

No Headlines